F-Tryptophan PET/CT in Human Cancers

Description

Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.

Conditions

Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors, Rectal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers

F-Tryptophan PET/CT in Human Cancers

Condition
Intracranial Glioma
Intervention / Treatment

-

Contacts and Locations

Detroit

Karmanos Cancer Institute, Detroit, Michigan, United States, 48201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years.
  • * Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.
  • * Patient is able to lie in the PET/CT scanner for at least 70 minutes while undergoing scanning.
  • * Women of childbearing potential must not be pregnant or breastfeeding.
  • * Recent anatomic imaging with visible disease (tumor) for comparison with the PET/CT. .
  • * Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.
  • * Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
  • * Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.
  • * ECOG performance status of 2 or better.
  • * Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \[LAR\], depot) for \>3 months before enrollment may be enrolled on the study, but such treatment is not required.
  • * Clinical and radiological diagnosis of a breast cancer
  • * ECOG performance status of 2 or better.
  • * Histologically confirmed colorectal cancer, which is located in the rectum.
  • * ECOG performance status of 2 or better.
  • * Patients who are pregnant or lactating are excluded.
  • * Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.
  • * Tumor surgery or radiation within 1 month prior to the PET scan
  • * Tumor-directed therapy within 3 months to the area of planned imaging.
  • * Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).
  • * Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Barbara Ann Karmanos Cancer Institute,

Csaba Juhasz, M.D.,Ph.D, PRINCIPAL_INVESTIGATOR, Barbara Ann Karmanos Cancer Institute

Study Record Dates

2024-12-31